Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations.
BACKGROUND
In selected patients with peritoneal carcinomatosis from colorectal cancer prognosis can be improved by hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The aim of this study was to evaluate the tumor response of peritoneal carcinomatosis in tumor-bearing rats treated with HIPEC.


METHODS
CC531 colon carcinoma (2,5 x 106 cells), implanted intraperitoneally in Wag/Rija rats, was treated by hyperthermic intraperitoneal chemotherapy. After 10 days of tumor growth the animals were randomized into five groups of six animals each: group I: control (n = 6), group II: sham operated animals (n = 6), group III: hyperthermic intraperitoneal perfusion (HIP) without cytostatic drugs, group IV: HIPEC with mitomycin C in a concentration of 15 mg/m2 (n = 6), group V: mitomycin C i.p. alone in a concentration of 10 mg/m2 (n = 6). After 10 days the extent of tumor spread and histological outcome were analysed by autopsy.


RESULTS
All control animals developed extensive intraperitoneal tumor growth. Histological tumor load was significantly reduced in group III and group V and was lowest in group IV. In group II tumor load was significantly higher than in group I. Implanted metastases were significantly decreased in group IV compared with group I and group II.


CONCLUSIONS
These findings indicate that HIPEC is an effective treatment for peritoneal carcinomatosis in this animal model. HIPEC reduced macroscopic and microscopic intraperitoneal tumor spread.
Pelz
Joerg O W
JO
Department of Surgery, University of Erlangen-Nuremberg, Germany. joerg.pelz@chir.imed.uni-erlangen.de
Doerfer
J
J
Dimmler
A
A
Hohenberger
W
W
Meyer
T
T
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D002470:Cell Survival; D010478:Chemotherapy, Cancer, Regional Perfusion; D003110:Colonic Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D006979:Hyperthermia, Induced; D007813:Laparotomy; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage* / Q000627:therapeutic use; D009368:Neoplasm Transplantation; D018365:Neoplasm, Residual; D010529:Peritoneal Cavity; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013047:Specific Pathogen-Free Organisms; D047368:Tumor Burden / Q000187:drug effects
D000970:Antineoplastic Agents; D016685:Mitomycin